ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Eli Lilly and Celltrion side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Eli LillyCelltrion
studies on the registry2,26284
open to participants now1734
phase 3 studies under way1045
reach primary completion within a year1046
programswith a study of their own in two years93+3 named only15

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseEli LillyCelltrion
Phase 1

Eli Lilly: 42 of its 93 programs at phase 1

  1. LY4256984phase 1
  2. LY3981314phase 1
  3. LY4167586phase 1
  4. LY4405094phase 1
  5. LY3873862phase 1

and 37 more — sign in to see them all

45%

Celltrion: 6 of its 15 programs at phase 1

  1. ixekizumabphase 1
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. CT-P52phase 1
  5. CTL02phase 1

and 1 more — sign in to see them all

40%
Phase 2

Eli Lilly: 28 of its 93 programs at phase 2

  1. macupatidephase 2
  2. LY4065967phase 2
  3. zotemtegrastphase 2
  4. LY4515100phase 2
  5. LY4005130phase 2

and 23 more — sign in to see them all

30%
00%
Phase 3

Eli Lilly: 13 of its 93 programs at phase 3

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. Imlunestrantphase 3

and 8 more — sign in to see them all

14%

Celltrion: 9 of its 15 programs at phase 3

  1. CT-P55phase 3
  2. CT-P51phase 3
  3. daratumumabphase 3
  4. empagliflozinphase 3
  5. CT-P43phase 3

and 4 more — sign in to see them all

60%
Approved, new studies

Eli Lilly: 10 of its 93 programs at approved, new studies

  1. Tirzepatideapproved, new study
  2. abemaciclibapproved, new study
  3. pirtobrutinibapproved, new study
  4. selpercatinibapproved, new study
  5. donanemabapproved, new study

and 5 more — sign in to see them all

11%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Eli Lilly49 readouts · 5 phase 3

Eli Lilly, Nov ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. abemaciclibapproved, new study · Nov 0 · NCT07818967
  2. BPL-003phase 2 · Nov 0 · NCT05660642
  3. brenipatidephase 3 · Nov 0 · NCT06606106
  4. LY3938577phase 2 · Nov 0 · NCT07215312
  5. LY4515100phase 2 · Nov 0 · NCT07511816

and 2 more — sign in to see them all

Eli Lilly, Dec ’26: 5 programs whose next study reaches primary completion

  1. eloralintidephase 3 · Dec 0 · NCT07738614
  2. GIPR Agonist LY3537021phase 2 · Dec 0 · NCT07169851
  3. LY4167586phase 1 · Dec 0 · NCT07225556
  4. ORN252phase 1 · Dec 0 · NCT07439796
  5. ORX750phase 2 · Dec 0 · NCT06752668

Eli Lilly, Jan ’27: 2 programs whose next study reaches primary completion

  1. LY4355756phase 1 · Jan 0 · NCT07765498
  2. parunoflastphase 2 · Jan 0 · NCT07867340

Eli Lilly, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3981314phase 1 · Feb 0 · NCT07005284
  2. mirikizumabapproved, new study · Feb 0 · NCT07446101
  3. orforglipronphase 3 · Feb 0 · NCT06672549

Eli Lilly, Mar ’27: 3 programs whose next study reaches primary completion

  1. lepodisiranphase 3 · Mar 0 · NCT07914738
  2. macupatidephase 2 · Mar 0 · NCT07215559
  3. solbinsiranphase 2 · Mar 0 · NCT07269210

Eli Lilly, Apr ’27: 3 programs whose next study reaches primary completion

  1. Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199phase 1 · Apr 0 · NCT07101328
  2. LY4065967phase 2 · Apr 0 · NCT05986292
  3. olomorasibphase 3 · Apr 0 · NCT04956640

Eli Lilly, May ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. clazakizumabphase 2 · May 0 · NCT07783802
  2. lebrikizumabapproved, new study · May 0 · NCT06338995
  3. LY4005130phase 2 · May 0 · NCT07533019
  4. nisotirostidephase 2 · May 0 · NCT06897475
  5. zotemtegrastphase 2 · May 0 · NCT07186101

Eli Lilly, Jun ’27: 4 programs whose next study reaches primary completion

  1. LY3839056 IVphase 1 · Jun 0 · NCT07945314
  2. LY4395089phase 2 · Jun 0 · NCT07483099
  3. vepugratinibphase 3 · Jun 0 · NCT05614739
  4. ORX489phase 1 · Jun 30 · NCT07413666

Eli Lilly, Jul ’27: 2 programs whose next study reaches primary completion

  1. LY4057996phase 1 · Jul 0 · NCT06945406
  2. LY4226695phase 1 · Jul 0 · NCT07767487

Eli Lilly, Aug ’27: 7 programs whose next study reaches primary completion

  1. Imlunestrantphase 3 · Aug 0 · NCT07918859
  2. LY3439539phase 1 · Aug 0 · NCT07598370
  3. LY4088044phase 1 · Aug 0 · NCT07090785
  4. LY4256984phase 1 · Aug 0 · NCT07100119
  5. LY4302814phase 1 · Aug 0 · NCT07566338

and 2 more — sign in to see them all

Eli Lilly, Sep ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3945262phase 1 · Sep 0 · NCT07943091
  2. LY4066708phase 1 · Sep 0 · NCT07046559
  3. LY4329090phase 1 · Sep 0 · NCT07808073
  4. mazdutidephase 2 · Sep 0 · NCT06143956
  5. naperiglipronphase 2 · Sep 0 · NCT06143956

and 1 more — sign in to see them all

Eli Lilly, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abdenoflastphase 2 · Oct 0 · NCT06836232
  2. pirtobrutinibapproved, new study · Oct 0 · NCT05254743
Celltrion3 readouts · 3 phase 3·

Celltrion, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinphase 3 · Dec 0 · NCT07093476
·

Celltrion, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CT-P51phase 3 · Feb 0 · NCT06939595

Celltrion, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. daratumumabphase 3 · Mar 8 · NCT06952478
·······
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Eli Lilly

New programs 8

Reached a new phase 2

Study stopped 0

None

Primary completion later 9

Celltrion

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 12 in all. A program counts in each condition its studies name most.

ConditionEli LillyCelltrion
Diabetes Mellitus, Type 2both · compare here

Eli Lilly in Diabetes Mellitus, Type 2: 10 programs

  1. orforglipronphase 3
  2. retatrutidephase 3
  3. macupatidephase 2
  4. naperiglipronphase 2
  5. mazdutidephase 2

and 5 more — sign in to see them all

Their studies: Eli Lilly’s studies of Diabetes Mellitus, Type 2 in search

Celltrion in Diabetes Mellitus, Type 2: 4 programs

  1. empagliflozinphase 3
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. L03TD1phase 1

Their studies: Celltrion’s studies of Diabetes Mellitus, Type 2 in search

Psoriasisboth · compare here

Eli Lilly in Psoriasis: 5 programs

  1. eltrekibartphase 2
  2. simepdekinraphase 2
  3. DC-806phase 2
  4. Tirzepatideapproved, new study
  5. mirikizumabapproved, new study

Their studies: Eli Lilly’s studies of Psoriasis in search

Celltrion in Psoriasis: 3 programs

  1. CT-P55phase 3
  2. CT-P43phase 3
  3. ixekizumabphase 1

Their studies: Celltrion’s studies of Psoriasis in search

Arthritis, Rheumatoidboth · compare here

Eli Lilly in Arthritis, Rheumatoid: 4 programs

  1. clazakizumabphase 2
  2. sevoloprubartphase 2
  3. LY4213663phase 1
  4. baricitinibapproved, new study

Their studies: Eli Lilly’s studies of Arthritis, Rheumatoid in search

Celltrion in Arthritis, Rheumatoid: 2 programs

  1. CT-P13 SC Auto-Injectorphase 3
  2. ixekizumabphase 1

Their studies: Celltrion’s studies of Arthritis, Rheumatoid in search

Atherosclerosisboth · compare here

Eli Lilly in Atherosclerosis: 5 programs

  1. retatrutidephase 3
  2. lepodisiranphase 3
  3. muvalaplinphase 3
  4. VERVE-102phase 2
  5. clazakizumabphase 2

Their studies: Eli Lilly’s studies of Atherosclerosis in search

Celltrion in Atherosclerosis: 1 program

  1. Ezetimibephase 3

Their studies: Celltrion’s studies of Atherosclerosis in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Eli Lilly in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. olomorasibphase 3
  2. Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408phase 1
  3. abemaciclibapproved, new study
  4. selpercatinibapproved, new study

Their studies: Eli Lilly’s studies of Carcinoma, Non-Small-Cell Lung in search

Celltrion in Carcinoma, Non-Small-Cell Lung: 1 program

  1. CT-P51phase 3

Their studies: Celltrion’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 1both · compare here

Eli Lilly in Diabetes Mellitus, Type 1: 4 programs

  1. macupatidephase 2
  2. LY3938577phase 2
  3. LY4057996phase 1
  4. Tirzepatideapproved, new study

Their studies: Eli Lilly’s studies of Diabetes Mellitus, Type 1 in search

Celltrion in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Diabetes Mellitus, Type 1 in search

Hypertensionboth · compare here

Eli Lilly in Hypertension: 1 program

  1. orforglipronphase 3

Their studies: Eli Lilly’s studies of Hypertension in search

Celltrion in Hypertension: 3 programs

  1. rosuvastatinphase 3
  2. Amlodipinephase 3
  3. Ezetimibephase 3

Their studies: Celltrion’s studies of Hypertension in search

Arthritis, Psoriaticboth · compare here

Eli Lilly in Arthritis, Psoriatic: 1 program

  1. clazakizumabphase 2

Their studies: Eli Lilly’s studies of Arthritis, Psoriatic in search

Celltrion in Arthritis, Psoriatic: 1 program

  1. ixekizumabphase 1

Their studies: Celltrion’s studies of Arthritis, Psoriatic in search

Dyslipidemiasboth · compare here

Eli Lilly in Dyslipidemias: 1 program

  1. solbinsiranphase 2

Their studies: Eli Lilly’s studies of Dyslipidemias in search

Celltrion in Dyslipidemias: 1 program

  1. rosuvastatinphase 3

Their studies: Celltrion’s studies of Dyslipidemias in search

Heart Failureboth · compare here

Eli Lilly in Heart Failure: 1 program

  1. LY3971297phase 1

Their studies: Eli Lilly’s studies of Heart Failure in search

Celltrion in Heart Failure: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Heart Failure in search

Lymphoma, Mantle-Cellboth · compare here

Eli Lilly in Lymphoma, Mantle-Cell: 1 program

  1. pirtobrutinibapproved, new study

Their studies: Eli Lilly’s studies of Lymphoma, Mantle-Cell in search

Celltrion in Lymphoma, Mantle-Cell: 1 program

  1. daratumumabphase 3

Their studies: Celltrion’s studies of Lymphoma, Mantle-Cell in search

Renal Insufficiency, Chronicboth · compare here

Eli Lilly in Renal Insufficiency, Chronic: 1 program

  1. orforglipronphase 3

Their studies: Eli Lilly’s studies of Renal Insufficiency, Chronic in search

Celltrion in Renal Insufficiency, Chronic: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Renal Insufficiency, Chronic in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetEli LillyCelltrion
IL17Asimepdekinraixekizumabrule
A target, or a pathogen for a vaccine, known for: Eli Lilly 50 of 93 · Celltrion 6 of 15 programs (28 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Eli Lilly: 3).